The global oncologic disorders testing industry is exhibiting significant increase, propelled by a rising occurrence of myeloma and other related diseases. Analysts estimate the current market value to be substantial, with projections indicating a steady compound annual increase rate (CAGR) over the coming period. Key drivers shaping the landscape